Physician profile
Douglas B Fullerton
NPI 1831253863
$2,628.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $478 · 2022: $186 · 2023: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $185.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $371.78 | 2022-2023 | |
| Allergan, INC. | $349.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $305.65 | 2019-2020 | |
| Novo Nordisk INC | $271.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $193.75 | 2019-2020 | |
| Pfizer INC. | $180.64 | 2019-2020 | |
| Lilly USA, LLC | $171.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $145.77 | 2019 | |
| Amarin Pharma, INC. | $89.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $52.46 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $52.43 | 2019 | |
| Amgen INC. | $43.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.02 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.93 | 2019 | |
| Merck Sharp & Dohme LLC | $23.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Fullerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.